D. E. Shaw & Co., Inc. Intra Cellular Therapies, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 368,680 shares of ITCI stock, worth $31.5 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

368,680

Holding current value

$31.5 Million

% of portfolio

0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $14.4 Million - $17.1 Million	-211,679 Reduced 36.47%	368,680 $27 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $12.3 Million - $15.2 Million	190,080 Added 48.7%	580,359 $39.7 Million
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $7.81 Million - $9.17 Million	-121,271 Reduced 23.71%	390,279 $27 Million
Q4 2023 Feb 14, 2024	SELL	$46.37 - $73.65 $10.7 Million - $16.9 Million	-229,827 Reduced 31.0%	511,550 $36.6 Million
Q3 2023 Nov 14, 2023	SELL	$52.09 - $64.1 $11 Million - $13.6 Million	-211,465 Reduced 22.19%	741,377 $38.6 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $24.2 Million - $29.4 Million	442,938 Added 86.87%	952,842 $60.3 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $157,504 - $204,936	-3,596 Reduced 0.7%	509,904 $27.6 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $7.2 Million - $8.9 Million	163,422 Added 46.68%	513,500 $27.2 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $487,505 - $684,905	11,417 Added 3.37%	350,078 $16.3 Million
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $1.12 Million - $1.7 Million	-25,957 Reduced 7.12%	338,661 $19.3 Million
Q1 2022 May 16, 2022	BUY	$38.74 - $62.09 $8.18 Million - $13.1 Million	211,031 Added 137.4%	364,618 $22.3 Million
Q4 2021 Feb 14, 2022	BUY	$35.2 - $53.42 $5.41 Million - $8.2 Million	153,587 New	153,587 $8.04 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $1.38 Million - $2.04 Million	-48,063 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$29.3 - $44.5 $2.11 Million - $3.2 Million	-71,936 Reduced 59.95%	48,063 $1.96 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $680,556 - $873,012	22,096 Added 22.57%	119,999 $4.07 Million
Q4 2020 Feb 16, 2021	SELL	$23.34 - $32.22 $3.07 Million - $4.24 Million	-131,700 Reduced 57.36%	97,903 $3.11 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $854,401 - $1.55 Million	48,518 Added 26.79%	229,603 $5.89 Million
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $76,944 - $142,843	-5,362 Reduced 2.88%	181,085 $4.65 Million
Q1 2020 May 15, 2020	SELL	$12.31 - $33.12 $553,531 - $1.49 Million	-44,966 Reduced 19.43%	186,447 $2.87 Million
Q4 2019 Feb 14, 2020	BUY	$7.26 - $38.49 $13,699 - $72,630	1,887 Added 0.82%	231,413 $7.94 Million
Q3 2019 Nov 14, 2019	SELL	$7.47 - $14.03 $936,454 - $1.76 Million	-125,362 Reduced 35.32%	229,526 $1.71 Million
Q2 2019 Aug 14, 2019	BUY	$10.65 - $14.29 $454,009 - $609,182	42,630 Added 13.65%	354,888 $4.61 Million
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $977,588 - $1.26 Million	89,687 Added 40.3%	312,258 $3.8 Million
Q4 2018 Feb 14, 2019	BUY	$10.36 - $20.96 $287,572 - $581,807	27,758 Added 14.25%	222,571 $2.54 Million
Q3 2018 Nov 14, 2018	BUY	$17.77 - $22.9 $208,673 - $268,914	11,743 Added 6.41%	194,813 $4.23 Million
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $684,552 - $924,323	-39,501 Reduced 17.75%	183,070 $3.24 Million
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $2.8 Million - $4.7 Million	184,416 Added 483.33%	222,571 $4.69 Million
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $544,471 - $640,622	38,155	38,155 $552,000

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.05B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account